SCHEMBL5115962

SCHEMBL5115962

CCOC1Oc2c(c(=O)oc3cc(OC)ccc23)C1c1c(O)c2ccc(OC)cc2oc1=O

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NQO1 P15559 3/20 0.52
ALDH1A1 P00352 9/20 0.43
KDM4E B2RXH2 9/20 0.43
MAPT P10636 6/20 0.43
POLB P06746 2/20 0.43
NPC1 O15118 1/20 0.43
STAT1 P42224 1/20 0.43
RAB9A P51151 1/20 0.43
HPGD P15428 6/20 0.43
HSD17B10 Q99714 4/20 0.43
GAA P10253 3/20 0.43
LMNA P02545 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
MEN1 O00255 3/20 0.41
KMT2A Q03164 3/20 0.41
TP53 P04637 2/20 0.41
CYP3A4 P08684 2/20 0.41
CASP1 P29466 1/20 0.41
CASP7 P55210 1/20 0.41
CYP2C9 P11712 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5114980 0.90 NQO1 (0.52) NQO1ALDH1A1KDM4EMAPTPOLB
SCHEMBL5115619 0.87 NQO1 (0.38) NQO1ALDH1A1KDM4EMAPTHPGD
SCHEMBL5125455 0.86 TP53 (0.38) NQO1ALDH1A1KDM4EMAPTHPGD
SCHEMBL5114210 0.84 ALDH1A1 (0.47) NQO1ALDH1A1KDM4EMAPTHPGD
SCHEMBL5342077 0.84 NQO1 (0.54) NQO1ALDH1A1KDM4EMAPTPOLB
SCHEMBL5120322 0.81 NQO1 (0.46) NQO1ALDH1A1KDM4EHPGDHSD17B10
SCHEMBL5119698 0.80 PRNP (0.40) NQO1ALDH1A1KDM4EMAPTHPGD
SCHEMBL5111977 0.79 NQO1 (0.48) NQO1ALDH1A1KDM4EMAPTPOLB
SCHEMBL5114488 0.79 NQO1 (0.38) NQO1ALDH1A1KDM4EPOLBRAB9A
SCHEMBL5120361 0.78 NQO1 (0.53) NQO1ALDH1A1KDM4EMAPTPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7384975-B2 Substituted furochromenes, preparation thereof and their antiinflammatory action GLAXOSMITHKLINE ISTRAZIVACKI CENTAR ZAGREB D.O.O. (HR) 2008-06-10 US disclosed
US-20060148889-A1 Substituted furochromenes, preparation thereof and their antiinflammatory action PLIVA-ISTRAZIVACKI INSTITUT D.O.O. (HR) 2006-07-06 US disclosed
EP-1648902-A1 SUBSTITUTED FUROCHROMENES, PREPARATION THEREOF AND THEIR ANTIINFLAMMATORY ACTION PLIVA-ISTRAZIVACKI INSTITUT d.o.o. (HR) 2006-04-26 EP disclosed
WO-2005010007-A1 SUBSTITUTED FUROCHROMENES, PREPARATION THEREOF AND THEIR ANTIINFLAMMATORY ACTION PLIVA- ISTRAZIVACKI INSTITUT D.O.O. (HR) 2005-02-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060148889-A1 Substituted furochromenes, preparation thereof and their antiinflammatory action CYP11B2, CYP11B1, LTC4S NQO1 60/4885ALDH1A1 486/4885KDM4E 3765/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.